Cost-effectiveness analysis of sorafenib, lenvatinib, atezolizumab plus bevacizumab and sintilimab plus bevacizumab for the treatment of advanced hepatocellular carcinoma in China

Table 4 Other medical estimates and AE incidences

Other medical costs	Unit cost (US$)	Incidence
Other medical costs	Unit cost (US$)	Sorafenib	Lenvatinib	Atezolizumab-Bevacizumab	Sintilimab-Bevacizumab
General ward	8.4/day	/	/	5 days per cycle	5 days per cycle
Tests ^a	163.16/set	Once per month	Once per month	Once per month	Once per month
Adverse event	Cost/event
HFSR	4	12.00%
Hypertension	38.5		23.00%	15.20%	14%
Subsequent active treatment per patient	1774/month

AE adverse event, HFSR hand-foot skin reaction, MRI magnetic resonance imagin,TC total count
^aTests included abdominal ultrasound, MRI, hematological examination, and liver and kidney function. The tests with similar frequency for the two therapies were not included, e.g., TC tests (cost: US$326.31), which were performed once bi-monthly for each therapy

ISSN: 1478-7547